NCT07349537phase 1recruiting

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

Revolution Medicines, Inc.

ClinicalTrials.gov

574

Enrollment · estimated

Countries · 9 sites

2028-04

Primary completion

2 mo ago

Record updated

Commercial relevance

Trial record references molecular eligibility required.

Molecular eligibility required

Biomarker requirement language

Pathologically documented, locally advanced or metastatic KRAS G12V-mutated solid tumor malignancy.

Change timeline

No changes detected yet. The first refresh records a baseline snapshot; subsequent refreshes generate field-level changes.

Signals from this trial

New trial
55/100
Opportunity
New phase 1 trial NCT07349537 posted by Revolution Medicines, Inc.: "Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors".
ClinicalTrials.gov record updated 60 days ago.

Eligibility — raw, for validation

Inclusion Criteria:

* At least 18 years old and has provided informed consent.
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
* Pathologically documented, locally advanced or metastatic KRAS G12V-mutated solid tumor malignancy.
* Received and progressed or been intolerant to prior standard therapy (including targeted therapy) appropriate for tumor type and stage.
* Measurable per RECIST v1.1
* Adequate organ function (bone marrow, liver, kidney, coagulation).
* Able to take oral medications.

Exclusion Criteria:

* Primary central nervous system (CNS) tumors
* Prior therapy with KRAS G12V inhibitor or direct RAS-targeted therapy (eg. degraders and/or inhibitors).
* Any conditions that may affect the ability to take or absorb study drug.
* Major surgery within 28 days prior to receiving study drug(s).
* Patient is unable or unwilling to comply with protocol-required study visits or procedures.